Tempero Bio has secured $70 million in Series B financing led by 8VC to advance TMP-301 into Phase 2 trials for substance use disorders. The funds will be used to support two clinical trials focusing on alcohol and cocaine use disorders.
Amount Raised
$70 Million
Round Type
Series B
OaklandBiotechnologyHealth CareTherapeuticsBiopharmaInvestors
Description
Tempero Bio, Inc. has announced the closing of a $70 million Series B financing. This financing was led by 8VC, with participation from Aditum Bio, Khosla Ventures, and other investors. The proceeds will be allocated to advancing TMP-301 through two Phase 2 clinical trials for alcohol and cocaine use disorders
Quick answer
Tempero Bio raised $70 Million in a Series B round, dated March 24, 2025. Investors: Aditum Bio, Khosla Ventures and 8VC. Tempero Bio is based in Oakland, California, United States.
- How much did Tempero Bio raise?
- Tempero Bio raised $70 Million in a Series B round on March 24, 2025.
- Who invested in Tempero Bio?
- Aditum Bio, Khosla Ventures and 8VC are named as investors in this round.
- What does Tempero Bio do?
- Tempero Bio is a clinical-stage biopharmaceutical company committed to developing innovative treatments for substance use disorders—chronic, relapsing brain diseases with limited pharmacologic solutions.
- Where is Tempero Bio based and how big is it?
- Tempero Bio is based in Oakland, California, United States. Fundz records about 8 employees.
- Who are the decision-makers at Tempero Bio?
- Fundz holds 2 contacts at Tempero Bio. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biopharma around the same time
Companies in the same sectors as Tempero Bio that raised within 45 days of this round, from Fundz verified event records.
- Retension Pharmaceuticals raised $12M on April 22, 2025.
- Lipella Pharmaceuticals raised $9K (Seed) on March 17, 2025.
- Aligos Therapeutics raised $105M on February 11, 2025.
- Acasti raised $15M on February 10, 2025.
- ImmuneWalk Therapeutics raised $7M (Seed) on May 8, 2025.
- Avammune Therapeutics raised $12M (Series A) on May 7, 2025.
Who to call at Tempero Bio, and when
A new round usually means Tempero Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Tempero Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Tempero Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Tempero Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Tempero Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansTempero Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.